Yanuki
Finance / Stocks
Eli Lilly (LLY) has become a dominant player in the obesity market, largely driven by its GLP-1 injections Mounjaro and Zepbound. However, despite strong sales growth, Lilly's shares fell after an HSBC downgrade citing pricing pressures and...
Finance / Stocks
Eli Lilly (LLY) faces a setback in the weight loss drug market as its oral GLP-1 candidate, orforglipron, experiences FDA review delays. This article examines the implications and explores alternative investment opportunities in the pharmac...
Finance / Stocks
Eli Lilly's tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, has become the world's top-selling drug, surpassing Merck's Keytruda. This reflects the increasing demand for GLP-1 drugs and Eli Lilly's strong market pos...
Finance / Healthcare
The healthcare sector is facing a confluence of challenges, including potential tariffs on pharmaceuticals, increasing regulatory scrutiny, and evolving financial strategies. These factors are creating uncertainty and volatility in the mark...
